Canadian Cancer Trials Group Bulletins

General


Recent Publications

There were four recent publications -- three trial-related (BR.24, CL.2, and MA.21), and one statistics publication.

MA.21 -- Interim Analysis Publication
Burnell M, Levine MN, Chapman J-AW, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer (ONLINE). J Clin Oncol 2009.

http://jco.ascopubs.org/cgi/content/abstract/JCO.2009.22.1077v1

CL.2 -- Primary Analysis Publication
Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AMV, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. Letter to the editor: Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia (ONLINE). Leukemia 2009.

http://www.nature.com/leu/journal/vaop/ncurrent/full/leu2009205a.html

BR.24 -- Primary Analysis Publication
Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu T-E, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: Canadian Cancer Trials Group BR.24 study (ONLINE). J Clin Oncol 2009.

http://jco.ascopubs.org/cgi/content/abstract/JCO.2009.22.9427v1

Statistics
Cheng M-Y, Qiu P, Tan X, Tu D. Confidence intervals for the first crossing point of two hazard functions. Lifetime Data Anal 15: 441-54, 2009.

http://www.springerlink.com/content/2jg8253k74551464